Cardiff Oncology Q2 2024 GAAP EPS $(0.26) Misses $(0.25) Estimate, Sales $163.000K Beat $58.750K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cardiff Oncology (NASDAQ:CRDF) reported Q2 2024 GAAP EPS of $(0.26), missing the $(0.25) estimate, but achieved sales of $163.000K, significantly beating the $58.750K estimate.
August 08, 2024 | 9:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology reported a Q2 2024 GAAP EPS of $(0.26), missing the $(0.25) estimate, but achieved sales of $163.000K, significantly beating the $58.750K estimate.
Despite missing EPS estimates by a small margin, Cardiff Oncology's significant sales beat and year-over-year sales growth of 50.93% are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100